Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Análisis de ratios de rentabilidad 
Datos trimestrales

Microsoft Excel

Ratios de rentabilidad (resumen)

AbbVie Inc., ratios de rentabilidad (datos trimestrales)

Microsoft Excel
31 mar 2025 31 dic 2024 30 sept 2024 30 jun 2024 31 mar 2024 31 dic 2023 30 sept 2023 30 jun 2023 31 mar 2023 31 dic 2022 30 sept 2022 30 jun 2022 31 mar 2022 31 dic 2021 30 sept 2021 30 jun 2021 31 mar 2021 31 dic 2020 30 sept 2020 30 jun 2020 31 mar 2020
Ratios de ventas
Ratio de margen de beneficio bruto 70.69% 69.99% 67.21% 62.75% 62.28% 62.42% 65.76% 68.91% 69.43% 70.00% 69.62% 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41%
Ratio de margen de beneficio operativo 17.56% 16.22% 24.89% 22.31% 23.50% 23.49% 27.32% 31.03% 28.49% 31.21% 30.59% 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81%
Ratio de margen de beneficio neto 7.31% 7.59% 9.22% 9.71% 11.02% 8.95% 11.81% 15.50% 13.37% 20.39% 23.19% 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08%
Ratios de inversión
Ratio de rendimiento sobre el capital contable (ROE) 295.42% 128.66% 84.91% 78.77% 74.85% 46.94% 53.86% 67.50% 57.14% 68.60% 83.83% 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30%
Ratio de rentabilidad sobre activos (ROA) 3.08% 3.17% 3.57% 3.76% 4.03% 3.61% 4.78% 6.42% 5.64% 8.53% 9.49% 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07%

Basado en los informes: 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31).



Ratio de margen de beneficio bruto

AbbVie Inc., ratio de margen de beneficio bruto, cálculo (datos trimestrales)

Microsoft Excel
31 mar 2025 31 dic 2024 30 sept 2024 30 jun 2024 31 mar 2024 31 dic 2023 30 sept 2023 30 jun 2023 31 mar 2023 31 dic 2022 30 sept 2022 30 jun 2022 31 mar 2022 31 dic 2021 30 sept 2021 30 jun 2021 31 mar 2021 31 dic 2020 30 sept 2020 30 jun 2020 31 mar 2020
Datos financieros seleccionados (US$ en millones)
Margen bruto 9,341 10,706 10,248 10,260 8,216 8,597 7,442 9,625 8,239 10,951 9,790 10,413 9,486 10,566 9,952 9,436 8,797 9,174 7,852 6,714 6,677
Ingresos netos 13,343 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583 13,538 14,886 14,342 13,959 13,010 13,858 12,902 10,425 8,619
Ratio de rentabilidad
Ratio de margen de beneficio bruto1 70.69% 69.99% 67.21% 62.75% 62.28% 62.42% 65.76% 68.91% 69.43% 70.00% 69.62% 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41%
Referencia
Ratio de margen de beneficio brutoCompetidores2
Amgen Inc. 61.48% 59.85% 58.71% 61.56% 64.76% 68.60% 72.35% 72.87% 73.65% 74.17% 73.99% 74.00% 73.30% 73.44% 74.00% 73.97% 74.37% 74.59%
Bristol-Myers Squibb Co. 70.47% 71.08% 74.91% 75.38% 75.71% 76.24% 76.54% 77.01% 77.68% 78.04% 78.82% 79.13% 79.62% 78.57% 76.92% 75.88% 74.42% 72.31%
Danaher Corp. 59.74% 59.50% 59.37% 59.27% 58.39% 58.74% 58.77% 59.17% 60.22% 60.21% 60.65% 60.77% 60.77% 60.95% 60.44% 59.24% 57.60% 55.98%
Eli Lilly & Co. 81.70% 81.31% 80.91% 80.75% 80.16% 79.25% 78.67% 77.77% 77.67% 76.77% 75.61% 75.98% 74.40% 74.18% 74.85% 74.27% 75.88% 77.66%
Gilead Sciences Inc. 78.17% 78.15% 75.98% 75.56% 75.62% 75.87% 78.66% 79.27% 78.94% 79.03% 74.31% 75.30% 75.50% 75.56% 80.23% 79.90% 80.32% 81.23%
Johnson & Johnson 68.30% 69.07% 69.05% 69.06% 69.20% 68.82% 68.54% 68.06% 67.34% 67.26% 67.43% 67.86% 67.97% 68.16% 67.51% 67.00% 66.24% 65.58%
Merck & Co. Inc. 76.42% 76.32% 75.82% 75.25% 74.37% 73.17% 72.86% 72.96% 72.43% 70.63% 70.49% 70.41% 70.72% 72.02% 67.95% 67.48% 66.99% 67.74%
Pfizer Inc. 72.28% 71.94% 67.73% 58.18% 58.09% 58.10% 60.97% 69.61% 68.61% 65.77% 65.53% 62.18% 60.35% 62.08% 65.28% 70.96% 76.46% 79.26%
Regeneron Pharmaceuticals Inc. 85.79% 86.13% 86.12% 86.16% 86.32% 86.16% 85.96% 86.42% 86.96% 87.18% 85.39% 84.97% 84.65% 84.83% 86.65% 86.85% 86.84% 86.82%
Thermo Fisher Scientific Inc. 41.34% 41.28% 40.77% 40.76% 40.40% 39.90% 39.87% 39.75% 40.28% 42.24% 44.42% 46.63% 48.37% 50.08% 51.05% 51.29% 51.47% 49.67%
Vertex Pharmaceuticals Inc. 86.03% 86.11% 86.12% 86.45% 86.86% 87.21% 87.80% 87.92% 88.04% 87.90% 88.00% 88.13% 87.95% 88.06% 87.94% 87.89% 88.06% 88.14%

Basado en los informes: 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31).

1 Q1 2025 cálculo
Ratio de margen de beneficio bruto = 100 × (Margen brutoQ1 2025 + Margen brutoQ4 2024 + Margen brutoQ3 2024 + Margen brutoQ2 2024) ÷ (Ingresos netosQ1 2025 + Ingresos netosQ4 2024 + Ingresos netosQ3 2024 + Ingresos netosQ2 2024)
= 100 × (9,341 + 10,706 + 10,248 + 10,260) ÷ (13,343 + 15,102 + 14,460 + 14,462) = 70.69%

2 Haga clic en el nombre del competidor para ver los cálculos.


Ratio de margen de beneficio operativo

AbbVie Inc., ratio de margen de beneficio operativo, cálculo (datos trimestrales)

Microsoft Excel
31 mar 2025 31 dic 2024 30 sept 2024 30 jun 2024 31 mar 2024 31 dic 2023 30 sept 2023 30 jun 2023 31 mar 2023 31 dic 2022 30 sept 2022 30 jun 2022 31 mar 2022 31 dic 2021 30 sept 2021 30 jun 2021 31 mar 2021 31 dic 2020 30 sept 2020 30 jun 2020 31 mar 2020
Datos financieros seleccionados (US$ en millones)
Utilidad operativa 3,733 (1,490) 3,831 3,998 2,798 3,195 2,281 4,513 2,768 5,502 4,603 3,295 4,717 5,074 4,306 4,441 4,103 3,753 3,255 752 3,603
Ingresos netos 13,343 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583 13,538 14,886 14,342 13,959 13,010 13,858 12,902 10,425 8,619
Ratio de rentabilidad
Ratio de margen de beneficio operativo1 17.56% 16.22% 24.89% 22.31% 23.50% 23.49% 27.32% 31.03% 28.49% 31.21% 30.59% 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81%
Referencia
Ratio de margen de beneficio operativoCompetidores2
Amgen Inc. 22.71% 22.66% 19.97% 20.96% 24.72% 29.35% 34.55% 37.50% 36.07% 38.57% 39.31% 38.04% 32.78% 31.44% 30.14% 30.72% 37.23% 37.70%
Bristol-Myers Squibb Co. 15.24% -15.50% -14.05% -14.39% -14.30% 16.18% 16.96% 17.29% 18.13% 17.96% 19.04% 18.19% 16.79% 15.91% -15.73% -17.02% -19.19% -21.60%
Danaher Corp. 20.26% 20.37% 20.11% 21.22% 21.05% 21.77% 23.83% 25.06% 27.02% 27.61% 27.35% 25.44% 25.23% 25.35% 24.63% 25.04% 22.30% 18.99%
Eli Lilly & Co. 28.74% 28.64% 24.81% 23.28% 20.80% 18.92% 18.42% 24.17% 22.45% 24.97% 24.65% 25.50% 25.94% 22.45% 23.17% 21.81% 22.06% 24.69%
Gilead Sciences Inc. 28.77% 5.81% 2.92% 9.26% 5.79% 28.24% 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56% 36.72% 42.79% 37.20% 18.07% 16.72%
Johnson & Johnson 23.59% 23.42% 24.42% 25.31% 25.04% 24.90% 25.55% 25.61% 25.21% 24.63% 23.89% 23.47% 23.76% 24.95% 24.69% 25.23% 24.10% 23.60%
Merck & Co. Inc. 31.51% 31.03% 21.60% 24.75% 6.93% 3.92% 13.08% 10.34% 27.85% 30.27% 30.66% 33.04% 28.85% 25.74% 14.07% 10.64% 14.02% 16.47%
Pfizer Inc. 19.29% 19.51% 9.56% -4.19% -2.08% 2.15% 14.36% 28.13% 34.44% 34.83% 33.59% 30.37% 26.12% 23.91% 24.67% 24.12% 21.20% 19.47%
Regeneron Pharmaceuticals Inc. 27.20% 28.10% 28.69% 28.95% 29.40% 30.85% 32.23% 34.20% 35.79% 38.93% 45.45% 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09%
Thermo Fisher Scientific Inc. 17.23% 17.11% 16.93% 17.01% 16.38% 16.00% 15.81% 15.42% 16.29% 18.69% 20.54% 22.51% 23.83% 25.57% 27.04% 28.00% 27.68% 24.19%
Vertex Pharmaceuticals Inc. -6.69% -2.11% -2.54% -3.37% 41.16% 38.83% 40.16% 41.72% 43.93% 48.23% 47.72% 48.85% 36.93% 36.73% 37.17% 33.93% 47.14% 46.03%

Basado en los informes: 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31).

1 Q1 2025 cálculo
Ratio de margen de beneficio operativo = 100 × (Utilidad operativaQ1 2025 + Utilidad operativaQ4 2024 + Utilidad operativaQ3 2024 + Utilidad operativaQ2 2024) ÷ (Ingresos netosQ1 2025 + Ingresos netosQ4 2024 + Ingresos netosQ3 2024 + Ingresos netosQ2 2024)
= 100 × (3,733 + -1,490 + 3,831 + 3,998) ÷ (13,343 + 15,102 + 14,460 + 14,462) = 17.56%

2 Haga clic en el nombre del competidor para ver los cálculos.


Ratio de margen de beneficio neto

AbbVie Inc., ratio de margen de beneficio neto, cálculo (datos trimestrales)

Microsoft Excel
31 mar 2025 31 dic 2024 30 sept 2024 30 jun 2024 31 mar 2024 31 dic 2023 30 sept 2023 30 jun 2023 31 mar 2023 31 dic 2022 30 sept 2022 30 jun 2022 31 mar 2022 31 dic 2021 30 sept 2021 30 jun 2021 31 mar 2021 31 dic 2020 30 sept 2020 30 jun 2020 31 mar 2020
Datos financieros seleccionados (US$ en millones)
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. 1,286 (22) 1,561 1,370 1,369 822 1,778 2,024 239 2,473 3,949 924 4,490 4,044 3,179 766 3,553 36 2,308 (738) 3,010
Ingresos netos 13,343 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583 13,538 14,886 14,342 13,959 13,010 13,858 12,902 10,425 8,619
Ratio de rentabilidad
Ratio de margen de beneficio neto1 7.31% 7.59% 9.22% 9.71% 11.02% 8.95% 11.81% 15.50% 13.37% 20.39% 23.19% 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08%
Referencia
Ratio de margen de beneficio netoCompetidores2
Amgen Inc. 18.10% 12.77% 13.58% 10.60% 13.35% 24.96% 29.52% 31.52% 31.77% 26.42% 27.88% 26.73% 23.42% 24.25% 23.03% 23.80% 29.60% 29.97%
Bristol-Myers Squibb Co. 11.38% -18.53% -15.30% -14.06% -13.50% 17.83% 18.44% 17.62% 15.95% 13.71% 14.29% 14.04% 13.31% 15.08% -11.89% -11.44% -14.53% -21.20%
Danaher Corp. 15.81% 16.33% 16.39% 17.83% 18.54% 19.94% 22.89% 22.80% 23.32% 22.91% 21.65% 20.61% 21.32% 21.84% 20.97% 21.00% 19.17% 16.36%
Eli Lilly & Co. 22.66% 23.51% 20.48% 18.86% 17.08% 15.36% 15.55% 22.01% 20.54% 21.88% 20.63% 19.58% 20.90% 19.71% 21.52% 22.71% 23.91% 25.24%
Gilead Sciences Inc. 20.87% 1.68% 0.45% 3.82% 1.78% 21.03% 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60% 23.05% 27.21% 19.62% 1.19% 0.51%
Johnson & Johnson 24.41% 15.84% 16.74% 43.91% 44.92% 41.28% 39.58% 14.52% 13.77% 18.90% 19.95% 19.21% 20.90% 22.26% 19.55% 19.92% 17.95% 17.82%
Merck & Co. Inc. 27.27% 26.68% 19.23% 21.98% 3.76% 0.61% 7.77% 5.34% 22.52% 24.49% 25.88% 29.00% 26.27% 26.79% 15.09% 11.83% 15.09% 14.72%
Pfizer Inc. 12.62% 12.62% 7.04% -4.62% -0.55% 3.56% 15.13% 27.38% 31.19% 31.27% 29.81% 28.94% 27.01% 27.04% 28.77% 23.86% 24.03% 22.95%
Regeneron Pharmaceuticals Inc. 31.94% 31.07% 33.61% 32.04% 29.45% 30.14% 30.47% 33.93% 33.81% 35.64% 39.17% 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35%
Thermo Fisher Scientific Inc. 15.18% 14.77% 14.48% 14.69% 14.20% 13.99% 13.68% 13.14% 13.75% 15.47% 15.92% 17.37% 18.49% 19.70% 21.93% 22.47% 22.08% 19.79%
Vertex Pharmaceuticals Inc. -8.91% -4.86% -4.52% -4.74% 39.46% 36.68% 35.94% 35.40% 35.40% 37.20% 37.62% 38.26% 30.84% 30.92% 30.52% 29.80% 43.06% 43.70%

Basado en los informes: 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31).

1 Q1 2025 cálculo
Ratio de margen de beneficio neto = 100 × (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2025 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2024 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2024 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2024) ÷ (Ingresos netosQ1 2025 + Ingresos netosQ4 2024 + Ingresos netosQ3 2024 + Ingresos netosQ2 2024)
= 100 × (1,286 + -22 + 1,561 + 1,370) ÷ (13,343 + 15,102 + 14,460 + 14,462) = 7.31%

2 Haga clic en el nombre del competidor para ver los cálculos.


Ratio de rendimiento sobre el capital contable (ROE)

AbbVie Inc., ROE, cálculo (datos trimestrales)

Microsoft Excel
31 mar 2025 31 dic 2024 30 sept 2024 30 jun 2024 31 mar 2024 31 dic 2023 30 sept 2023 30 jun 2023 31 mar 2023 31 dic 2022 30 sept 2022 30 jun 2022 31 mar 2022 31 dic 2021 30 sept 2021 30 jun 2021 31 mar 2021 31 dic 2020 30 sept 2020 30 jun 2020 31 mar 2020
Datos financieros seleccionados (US$ en millones)
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. 1,286 (22) 1,561 1,370 1,369 822 1,778 2,024 239 2,473 3,949 924 4,490 4,044 3,179 766 3,553 36 2,308 (738) 3,010
Capital contable (déficit) 1,420 3,325 6,032 6,778 8,007 10,360 12,094 12,866 13,274 17,254 15,994 14,653 16,283 15,408 13,550 12,569 13,710 13,076 15,270 14,708 (7,415)
Ratio de rentabilidad
ROE1 295.42% 128.66% 84.91% 78.77% 74.85% 46.94% 53.86% 67.50% 57.14% 68.60% 83.83% 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30%
Referencia
ROECompetidores2
Amgen Inc. 95.59% 69.59% 56.20% 52.83% 74.93% 107.78% 98.82% 117.67% 148.04% 178.97% 187.11% 271.85% 624.78% 87.96% 68.26% 69.67% 75.91% 77.20%
Bristol-Myers Squibb Co. 31.16% -54.78% -42.34% -38.44% -37.28% 27.27% 28.57% 24.91% 22.97% 20.37% 20.44% 20.30% 19.79% 19.46% -14.52% -13.80% -16.54% -23.84%
Danaher Corp. 7.40% 7.87% 7.59% 8.42% 8.24% 8.91% 11.29% 12.30% 13.47% 14.39% 14.40% 13.63% 13.93% 14.24% 13.54% 13.12% 11.76% 9.17%
Eli Lilly & Co. 70.45% 74.62% 58.78% 54.14% 47.91% 48.65% 44.46% 58.73% 50.82% 58.64% 59.91% 66.61% 65.69% 62.16% 76.99% 94.20% 88.31% 109.79%
Gilead Sciences Inc. 31.13% 2.48% 0.69% 5.77% 2.77% 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68%
Johnson & Johnson 27.92% 19.68% 20.93% 53.14% 54.95% 51.11% 48.61% 17.37% 17.95% 23.36% 25.68% 24.05% 26.54% 28.20% 25.44% 25.53% 22.96% 23.25%
Merck & Co. Inc. 36.07% 36.96% 27.30% 31.52% 5.71% 0.97% 11.17% 8.04% 27.82% 31.57% 34.32% 38.34% 34.68% 34.17% 20.10% 16.73% 26.08% 27.91%
Pfizer Inc. 8.73% 9.11% 4.61% -2.96% -0.33% 2.38% 10.81% 21.68% 28.77% 32.79% 32.14% 33.61% 30.29% 28.47% 26.28% 18.86% 16.23% 15.21%
Regeneron Pharmaceuticals Inc. 15.31% 15.03% 15.87% 15.32% 14.29% 15.22% 16.03% 17.90% 17.80% 19.14% 25.05% 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86%
Thermo Fisher Scientific Inc. 13.19% 12.78% 12.52% 13.12% 13.26% 12.83% 13.11% 13.08% 14.26% 15.80% 16.15% 17.59% 18.56% 18.94% 22.13% 23.32% 22.60% 18.47%
Vertex Pharmaceuticals Inc. -5.99% -3.26% -3.07% -3.32% 21.67% 20.59% 21.01% 21.75% 22.59% 23.88% 25.12% 26.77% 22.47% 23.19% 22.83% 21.66% 30.76% 31.22%

Basado en los informes: 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31).

1 Q1 2025 cálculo
ROE = 100 × (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2025 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2024 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2024 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2024) ÷ Capital contable (déficit)
= 100 × (1,286 + -22 + 1,561 + 1,370) ÷ 1,420 = 295.42%

2 Haga clic en el nombre del competidor para ver los cálculos.


Ratio de rentabilidad sobre activos (ROA)

AbbVie Inc., ROA, cálculo (datos trimestrales)

Microsoft Excel
31 mar 2025 31 dic 2024 30 sept 2024 30 jun 2024 31 mar 2024 31 dic 2023 30 sept 2023 30 jun 2023 31 mar 2023 31 dic 2022 30 sept 2022 30 jun 2022 31 mar 2022 31 dic 2021 30 sept 2021 30 jun 2021 31 mar 2021 31 dic 2020 30 sept 2020 30 jun 2020 31 mar 2020
Datos financieros seleccionados (US$ en millones)
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. 1,286 (22) 1,561 1,370 1,369 822 1,778 2,024 239 2,473 3,949 924 4,490 4,044 3,179 766 3,553 36 2,308 (738) 3,010
Activos totales 136,165 135,161 143,422 141,937 148,874 134,711 136,221 135,367 134,544 138,805 141,325 143,186 143,211 146,529 148,858 147,972 150,501 150,565 149,621 149,530 91,199
Ratio de rentabilidad
ROA1 3.08% 3.17% 3.57% 3.76% 4.03% 3.61% 4.78% 6.42% 5.64% 8.53% 9.49% 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07%
Referencia
ROACompetidores2
Amgen Inc. 6.64% 4.45% 4.65% 3.44% 4.05% 6.91% 8.36% 8.84% 8.92% 10.06% 10.73% 11.09% 9.67% 9.63% 8.63% 9.61% 11.33% 11.54%
Bristol-Myers Squibb Co. 5.86% -9.66% -7.75% -6.91% -6.21% 8.43% 9.08% 8.52% 7.75% 6.53% 6.80% 6.59% 6.07% 6.40% -4.87% -4.58% -5.53% -7.61%
Danaher Corp. 4.76% 5.03% 4.83% 5.35% 5.28% 5.64% 6.74% 7.49% 8.15% 8.55% 8.35% 7.76% 7.74% 7.73% 7.13% 7.19% 6.30% 4.79%
Eli Lilly & Co. 12.42% 13.45% 11.07% 10.22% 9.60% 8.19% 8.61% 11.85% 10.70% 12.62% 12.71% 12.09% 13.06% 11.44% 12.39% 12.70% 13.01% 13.28%
Gilead Sciences Inc. 10.57% 0.81% 0.23% 1.97% 0.86% 9.12% 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16% 9.16% 11.02% 7.59% 0.45% 0.18%
Johnson & Johnson 11.26% 7.81% 8.24% 20.99% 22.37% 20.98% 20.85% 6.81% 6.49% 9.57% 10.94% 10.33% 11.12% 11.47% 9.98% 10.07% 8.76% 8.41%
Merck & Co. Inc. 15.14% 14.62% 10.34% 12.20% 2.18% 0.34% 4.32% 2.98% 12.09% 13.30% 14.25% 15.48% 13.29% 12.35% 7.70% 6.14% 7.73% 7.72%
Pfizer Inc. 3.79% 3.76% 1.94% -1.20% -0.14% 0.94% 4.87% 9.75% 14.85% 15.91% 15.32% 15.01% 13.58% 12.11% 11.10% 7.78% 7.01% 6.23%
Regeneron Pharmaceuticals Inc. 11.98% 11.69% 12.43% 11.98% 11.22% 11.95% 12.41% 14.02% 13.91% 14.85% 19.40% 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47%
Thermo Fisher Scientific Inc. 6.58% 6.51% 6.11% 6.32% 6.21% 6.07% 6.12% 6.08% 6.36% 7.15% 7.77% 8.21% 8.20% 8.12% 11.64% 12.70% 12.02% 9.23%
Vertex Pharmaceuticals Inc. -4.32% -2.38% -2.16% -2.43% 16.81% 15.92% 15.97% 16.54% 17.18% 18.30% 19.59% 20.50% 17.19% 17.44% 17.25% 16.30% 22.80% 23.07%

Basado en los informes: 10-Q (Fecha del informe: 2025-03-31), 10-K (Fecha del informe: 2024-12-31), 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31).

1 Q1 2025 cálculo
ROA = 100 × (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2025 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2024 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2024 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2024) ÷ Activos totales
= 100 × (1,286 + -22 + 1,561 + 1,370) ÷ 136,165 = 3.08%

2 Haga clic en el nombre del competidor para ver los cálculos.